oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00004102: Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | NYU Langone Health, National Cancer Institute (NCI) | Colorectal Cancer | 11/01 | | | |
NCT00006015: Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 26 | US | trastuzumab, Herceptin, fluorouracil, 5-FU, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/03 | | |
NCT00026299: Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | ZD1839, gefitinib, Iressa ®, oxaliplatin, Eloxatin ® | University of Chicago, National Cancer Institute (NCI) | Colorectal Cancer | 12/02 | 02/05 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00016952: Irinotecan or Fluorouracil Plus Leucovorin in Treating Patients With Previously Treated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 19 | US, Canada | fluorouracil, irinotecan hydrochloride, leucovorin calcium | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/04 | 10/09 | | |
NCT00070265: Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer |
|
|
| Terminated | 2 | 80 | US | oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda, therapeutic conventional surgery, laboratory biomarker analysis | National Cancer Institute (NCI) | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 09/04 | | | |
NCT00080951: Irinotecan, Fluorouracil, Leucovorin, and Oxaliplatin as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 14 | US | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 04/05 | 02/08 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
NCT00039208: Combination Chemotherapy in Treating Patients With Colorectal Cancer |
|
|
| Completed | 2 | | Europe | fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin | European Organisation for Research and Treatment of Cancer - EORTC | Colorectal Cancer | 08/05 | | | |
SAKK 41/04, NCT00227734: Capecitabine and Oxaliplatin With or Without Cetuximab in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 74 | Europe | capecitabine and oxaliplatin + cetuximab, capecitabine and oxaliplatin | Swiss Group for Clinical Cancer Research | Colorectal Cancer | 10/05 | 02/06 | | |
NCT00003834: Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 44 | US, Canada | fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 12/05 | 12/05 | | |
NCT00026234: Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver |
|
|
| Completed | 2 | 75 | US | floxuridine, 5-FUDR, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, capecitabine, CAPE, Ro 09-1978/000, Xeloda | National Cancer Institute (NCI), NSABP Foundation Inc | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 01/06 | | | |
NCT00070434: S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum |
|
|
| Withdrawn | 2 | 0 | US | capecitabine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, radiation therapy, Pyridoxine | Southwest Oncology Group, National Cancer Institute (NCI) | Colorectal Cancer | 02/06 | | | |
| Completed | 2 | 200 | US | ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen) | Mayo Clinic | Locally Advanced Unresectable or Stage IV Colorectal Cancer | 06/06 | 06/06 | | |
NCT00103298: Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, isolated perfusion, leucovorin calcium, melphalan, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | | 07/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00378066: Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer |
|
|
| Completed | 2 | 49 | RoW | Bevacizumab, Capecitabine, Oxaliplatin | Asan Medical Center | Metastatic Colorectal Cancer | 08/06 | 10/08 | | |
NCT00262808: GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer |
|
|
| Completed | 2 | 50 | US | sargramostim, fluorouracil, leucovorin calcium, oxaliplatin, adjuvant therapy, conventional surgery, neoadjuvant therapy | University of Rochester | Colorectal Cancer | 09/06 | 09/06 | | |
NCT00276861: Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer |
|
|
| Terminated | 2 | 10 | US | gemcitabine hydrochloride, oxaliplatin | University of Miami | Colorectal Cancer | 09/06 | 05/08 | | |
NCT00025142: Gefitinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, gefitinib, leucovorin calcium, oxaliplatin | Stanford University, National Cancer Institute (NCI) | Colorectal Cancer | | 11/06 | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
NCT00311610: Liposomal SN-38 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 30 | US | SN-38 liposome | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 01/07 | 06/10 | | |
OPUS, NCT00125034: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 344 | Europe, RoW | Cetuximab, Oxaliplatin | Merck KGaA, Darmstadt, Germany | Neoplasm Metastasis, Colorectal Cancer | 03/07 | 11/10 | | |
|
|
|
|
|
NCT00118105: S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, Avastin, NSC-704865, capecitabine, Xeloda, NSC-712807, oxaliplatin, NSC-266046, conventional surgery | Southwest Oncology Group, National Cancer Institute (NCI), Eastern Cooperative Oncology Group | Colorectal Cancer, Metastatic Cancer | 04/07 | 04/07 | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00016978: Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan |
|
|
| Completed | 2 | 40 | US, Canada | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | National Cancer Institute (NCI) | Colorectal Cancer | 06/07 | | | |
NCT00043004: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 119 | Europe, RoW | bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiofrequency ablation | European Organisation for Research and Treatment of Cancer - EORTC, Arbeitsgruppe Lebermetastasen und Tumoren, Institute of Cancer Research, United Kingdom | Colorectal Cancer, Metastatic Cancer | 06/07 | | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00056030: Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 73 | US | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer, Metastatic Cancer | 10/07 | | | |
| Completed | 2 | 150 | Europe, RoW | Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan, FOLFOX 6, FOLFIRI | Central European Cooperative Oncology Group | Metastatic Colorectal Cancer | | 10/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00416494: Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer |
|
|
| Completed | 2 | 50 | US | bevacizumab, oxaliplatin, Capecitabine | Herbert Hurwitz, MD, National Cancer Institute (NCI) | Colorectal Cancer | 01/08 | 08/14 | | |
NCT00381862: Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX |
|
|
| Completed | 2 | 54 | US | aprepitant, Emend, MK-869, L-758,298, L-754,030, dexamethasone, fluorouracil, 5-FU, irinotecan hydrochloride, Trade names: Camptosar®, Other names: Camptothecin-11, CPT-11, leucovorin calcium, Generic Name: Leucovorin, Other Names: Citrovorum Factor, Folinic Acid, oxaliplatin, Trade Name: Eloxatin, palonosetron hydrochloride, Aloxi, quality-of-life assessment | OHSU Knight Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer, Nausea and Vomiting | 03/08 | 07/08 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
NCT00755534: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC |
|
|
| Terminated | 2 | 68 | Europe | Irinotecan, CPT-11, Campto, Capecitabine, Xeloda, Cetuximab, Erbitux, Oxaliplatin, Eloxatin, LoHP | Hellenic Oncology Research Group, University Hospital of Crete | Colorectal Cancer | 11/08 | 11/08 | | |
NCT00290615: Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 30 | US | bevacizumab, Avastin, cetuximab, capecitabine, oxaliplatin | Herbert Hurwitz, National Cancer Institute (NCI) | Colorectal Cancer | 01/09 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
FOIB, NCT01163396: First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 57 | Europe | Bevacizumab, Irinotecan, Oxaliplatin, 5-fluorouracil/leucovorin | Gruppo Oncologico del Nord-Ovest | Colorectal Cancer Metastatic | 04/09 | 04/10 | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
NCT00386828: Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial |
|
|
| Completed | 2 | 43 | Canada | Bevacizumab: | British Columbia Cancer Agency | Advanced Colorectal Cancer | 05/09 | 05/09 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
| Completed | 2 | 46 | Europe | NGR-hTNF | AGC Biologics S.p.A. | Colorectal Cancer (CRC) | 06/09 | 04/13 | | |
FUTURE, NCT00439517: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. |
|
|
| Completed | 2 | 302 | Europe, RoW | UFOX + Cetuximab, FOLFOX4 + Cetuximab | Merck KGaA, Darmstadt, Germany | Previously Untreated Metastatic Colorectal Cancer | 06/09 | 05/12 | | |
|
|
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
NCT00296062: Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer |
|
|
| Terminated | 2 | 12 | US | bevacizumab, capecitabine, irinotecan hydrochloride, oxaliplatin | Case Comprehensive Cancer Center, National Cancer Institute (NCI) | Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific | 10/09 | 05/11 | | |
NCT00625183: Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma |
|
|
| Terminated | 2 | 5 | US | selenomethionine, capecitabine, oxaliplatin, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, radiation therapy | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Colorectal Cancer | 10/09 | 12/09 | | |
NCT00831181: Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer |
|
|
| Completed | 2 | 27 | US | 5-FU, fluorouracil, Oxaliplatin, Eloxatin, leucovorin, Folinic Acid, mesorectal excision | Beth Israel Medical Center | Colorectal Cancer | 11/09 | 11/09 | | |
NCT00321828: Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery |
|
|
| Completed | 2 | 90 | US | bevacizumab, fluorouracil, 5-FU, leucovorin, leucovorin calcium, oxaliplatin | NSABP Foundation Inc, National Cancer Institute (NCI) | Colorectal Cancer | 11/09 | 12/12 | | |
|
|
NCT00537823: Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement |
|
|
| Terminated | 2 | 9 | US | Cetuximab, Erbitux, Bevacizumab, Avastin, Leucovorin, Oxaliplatin, Fluorouracil | Washington University School of Medicine | Colorectal Cancer, Metastases | 12/09 | 07/11 | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00613080: Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer |
|
|
| Completed | 2 | 79 | Canada, US | capecitabine, oxaliplatin, 50 mg/m^2 IV over 2 hours weekly for five weeks starting on day 1 of radiotherapy., resection, radiation therapy, FOLFOX, Oxaliplatin, leucovorin, 5-fluorouracil | Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology | Colorectal Cancer | 01/10 | 12/16 | | |
NCT00220116: Phase II Trial Assessing Efficacy and Toxicity of Capecitabine and Oxaliplatin in the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 172 | Europe | Capecitabine, Oxaliplatin | Royal Marsden NHS Foundation Trust | Colorectal Cancer | | | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT01024504: Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Bevacizumab, Avastin | Hellenic Oncology Research Group, University Hospital of Crete | Metastatic Colorectal Cancer | 03/10 | 03/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
| Completed | 2 | 14 | Europe | Mangafodipir, Teslascan; ACT code V08CAE05, Placebo treatment (0.9% NaCl) | Egetis Therapeutics | Chemotherapy, Colon Cancer | 04/10 | 04/10 | | |
NCT00588900: Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab |
|
|
| Terminated | 2 | 5 | US | cediranib maleate, irinotecan hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Colorectal Cancer | 05/10 | 11/11 | | |
NCT00479752: Safety and Efficacy of Folfox4 + Weekly Cetuximab vs Folfox 4+Biweekly Cetuximab by Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 151 | Europe, RoW | FOLFOX4 (Oxaliplatin), Cetuximab | Central European Cooperative Oncology Group | Colorectal Cancer | 06/10 | 11/15 | | |
|
|
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) |
|
|
| Terminated | 2 | 65 | US | XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin® | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Adenocarcinoma, Colon Cancer | 12/10 | 12/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
| Completed | 2 | 30 | Europe | Irinotecan, CPT-11, Campto, Leukovorin, LV, Oxaliplatin, LoHP, Eloxatin, 5-FLUOROURACIL, 5-FU, Cetuximab, Erbitux | University Hospital of Crete | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
NCT00675012 / 2007-003668-24: NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 24 | Europe | NGR-hTNF, Oxaliplatin, capecitabine | AGC Biologics S.p.A. | Colon Cancer | 12/10 | 05/13 | | |
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00544349: Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery |
|
|
| Completed | 2 | 45 | Europe | cetuximab, fluorouracil, leucovorin calcium, oxaliplatin | Gustave Roussy, Cancer Campus, Grand Paris | Colorectal Cancer, Metastatic Cancer | 05/11 | | | |
|
NCT00660582: FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor |
|
|
| Completed | 2 | 152 | Europe | Cetuximab (Erbitux), Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid | Per Pfeiffer, Odense University Hospital | Metastatic Colorectal Cancer | 05/11 | 02/13 | | |
|
NCT00100841: Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer |
|
|
| Completed | 2 | 66 | US | cetuximab, C225, C225 monoclonal antibody, IMC-C225, MOAB C225, monoclonal antibody C225, bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, Avastin, rhuMAb VEGF, oxaliplatin, 1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP, leucovorin calcium, CF, CFR, LV, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU | National Cancer Institute (NCI) | Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Colon, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Stage IV Colon Cancer, Stage IV Rectal Cancer | 07/11 | 07/11 | | |
| Completed | 2 | 111 | Europe | FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium, zibotentan, laboratory biomarker analysis, pharmacogenomic studies | Cardiff University | Colorectal Cancer | 07/11 | 09/12 | | |
NCT01270438: Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil | National Cancer Institute (NCI) | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer | 08/11 | 08/13 | | |
| Completed | 2 | 37 | Europe | FOLFOXIRI + Panitumumab | Gruppo Oncologico del Nord-Ovest | Metastatic Colo-rectal Cancer | 10/11 | | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
FOSCO, NCT00889343 / 2008-000803-26: Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer |
|
|
| Terminated | 2 | 101 | Europe | Sorafenib, Nexavar, Placebo, Oxaliplatin or Irinotecan, Leucovorin, 5-Fluorouracil | AIO-Studien-gGmbH | Colorectal Neoplasms | 11/11 | 12/12 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00969033 / 2007-005675-34: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin |
|
|
| Terminated | 2 | 8 | Europe | CS-1008, irinotecan, Camptosar | Daiichi Sankyo, Inc. | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT00743678: Neoadjuvant FOLFOX6 + Cetuximab in Patients With Colorectal Cancer and Unresectable Liver Metastasis |
|
|
| Completed | 2 | 73 | RoW | FOLFOX6/cetuximab | Samsung Medical Center | Colorectal Cancer, Unresectable Liver Metastasis | 01/12 | 06/12 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |